Mitchell Elliott, MD
he/him/his
InstructorDownloadHi-Res Photo
About
Copy Link
Titles
Instructor
Departments & Organizations
- All Institutions
Education & Training
- Non Degree Program
- University of Toronto, Medical Oncology
- Non Degree Program
- University of Toronto, Internal Medicine
- MD
- University of Toronto
- BS
- University of Windsor
Board Certifications
Medical Oncology
- Certification Organization
- Royal College of Physicians & Surgeons of CANADA
- Original Certification Date
- 2024
Medical Oncology
- Certification Organization
- American Board of Internal Medicine
- Original Certification Date
- 2024
Internal Medicine
- Certification Organization
- Royal College of Physicians & Surgeons of CANADA
- Original Certification Date
- 2022
Internal Medicine
- Certification Organization
- American Board of Internal Medicine
- Original Certification Date
- 2022
Research
Copy Link
Overview
Medical Research Interests
Breast Neoplasms; Circulating Tumor DNA; Drug Development; Drug Resistance; Xenograft Model Antitumor Assays
ORCID
0000-0001-6711-7287
Research at a Glance
Publications Timeline
A big-picture view of Mitchell Elliott's research output by year.
25Publications
444Citations
Publications
2025
Circulating tumor DNA as a biomarker in early phase clinical trials
. Circulating tumor DNA as a biomarker in early phase clinical trials. Cancer Cell 2025, 44: 240-247. PMID: 41418771, DOI: 10.1016/j.ccell.2025.11.011.Peer-Reviewed Original ResearchCitationsAltmetricA retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases
. A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases. Therapeutic Advances In Medical Oncology 2025, 17: 17588359251367315. PMID: 41164205, PMCID: PMC12559634, DOI: 10.1177/17588359251367315.Peer-Reviewed Original ResearchAltmetricPersonalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy
. Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy. Npj Breast Cancer 2025, 11: 74. PMID: 40683861, PMCID: PMC12276344, DOI: 10.1038/s41523-025-00783-2.Peer-Reviewed Original ResearchCitationsAltmetricThe Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative
. The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative. Cancer Cell 2025, 43: 587-592. PMID: 40185094, DOI: 10.1016/j.ccell.2025.03.014.Peer-Reviewed Original ResearchCitationsAltmetricLongitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay
. Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay. Nature Communications 2025, 16: 1837. PMID: 39984446, PMCID: PMC11845481, DOI: 10.1038/s41467-025-56658-4.Peer-Reviewed Original ResearchCitationsAltmetricUltrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
. Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer. Clinical Cancer Research 2025, 31: 1520-1532. PMID: 39785866, PMCID: PMC11994999, DOI: 10.1158/1078-0432.ccr-24-3472.Peer-Reviewed Original ResearchCitationsAltmetric
2024
Ionizable Drugs Enable Intracellular Delivery of Co‐Formulated siRNA
. Ionizable Drugs Enable Intracellular Delivery of Co‐Formulated siRNA. Advanced Materials 2024, 36: e2403701. PMID: 39148215, DOI: 10.1002/adma.202403701.Peer-Reviewed Original ResearchCitationsAltmetricEnhancing Early-Stage Breast Cancer Survivorship: Evidence-Based Strategies, Surveillance Testing, and Imaging Guidelines.
. Enhancing Early-Stage Breast Cancer Survivorship: Evidence-Based Strategies, Surveillance Testing, and Imaging Guidelines. American Society Of Clinical Oncology Educational Book 2024, 44: e432564. PMID: 38815189, DOI: 10.1200/edbk_432564.Peer-Reviewed Original ResearchCitationsAltmetricComparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer
. Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer. Scientific Reports 2024, 14: 3129. PMID: 38326452, PMCID: PMC10850180, DOI: 10.1038/s41598-024-53151-8.Peer-Reviewed Original ResearchCitationsAltmetric
2023
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages
. Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. Cell Reports 2023, 42: 113382. PMID: 37883228, DOI: 10.1016/j.celrep.2023.113382.Peer-Reviewed Original ResearchCitationsAltmetric
Academic Achievements & Community Involvement
Copy Link
Get In Touch
Copy Link
Contacts
Mailing Address
Yale Cancer Center
300 George St
New Haven, CONNECTICUT 06511-6624
United States